Michael E. Castagna
CEO & DirectorDr. Michael E. Castagna, Pharm.D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016 until July 12, 2017 and served as its Corporate Vice President since March 2016. Dr. Castagna leads commercialization efforts for Afrezza. Dr. Castagna has many years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joined MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs and Vice President, Global Lifecycle Management. Prior to Amgen, Dr. Castagna, was Executive Director of Bristol-Myers Squibb’s Immunology franchise from 2010 to 2012, where he served as co-lead to relaunch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone. Prior to Sandoz, Dr. Castagna held a variety of positions with EMD (Merck), Serono, Pharmasset and DuPont Pharmaceuticals. Dr. Castagna has been Director of MannKind Corporation since May 25, 2017. Dr. Castagna serves on the board of directors of Pet Partners headquartered in Bellevue, Washington. Dr. Castagna received his Bachelors of Science – Pharmacy degree from Philadelphia College of Pharmacy, his Doctor of Pharmacy from Massachusetts College of Pharmacy and his MBA from the Wharton School of Business at the University of Pennsylvania.
Positions
- Company NameMannKind CorporationStock CodeMNKDPositionCEO & DirectorColleagues
- JSJames S. ShannonIndependent Chairman
- CBChristopher B. PrentissChief Financial Officer
- DBDavid B. ThomsonExecutive VP, General Counsel & Secretary
- SAStuart A. TrossChief People & Workplace Officer
- DMDominic MarascoPresident of Endocrine Business Unit
- KKKent KresaChairman Emeritus
- RJRonald J. ConsiglioIndependent Director
- ACAnthony C. HooperIndependent Director
